共 1728 条
[1]
Le Gouill S(2017)Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma N Engl J Med 377 1250-1260
[2]
Thieblemont C(2017)Obinutuzumab for the first-line treatment of follicular lymphoma N Engl J Med 377 1331-1344
[3]
Oberic L(2019)Obinutuzumab in combination with chemotherapy for the first-line treatment of patients with advanced follicular lymphoma: an evidence review group evaluation of the NICE single technology appraisal Pharmacoeconomics 37 975-984
[4]
Moreau A(2019)Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL Blood 134 1024-1036
[5]
Bouabdallah K(2017)Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer 117 1736-1742
[6]
Dartigeas C(2016)Antibody drug conjugates: lessons from 20 years of clinical experience Ann Oncol 27 2168-2172
[7]
Damaj G(2019)Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study J Clin Oncol 37 3081-3089
[8]
Gastinne T(2019)Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group) Ann Oncol 30 612-620
[9]
Ribrag V(2020)Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin Exp Rev Clin Pharmacol 13 1073-1083
[10]
Feugier P(2020)Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma Exp Opin Investig Drugs 29 1079-1088